Mutations in FLT3, either internal tandem duplications (ITD) within the juxtamembrane domain or point mutations in the kinase domain, both leading to constitutive kinase activation, are prevalent in AML patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.